ArticleTranslational andrology and urology2025
Extraperitoneal laparoscopic versus transperitoneal robot-assisted laparoscopic approaches during radical prostatectomy for low-risk or intermediate-risk prostate cancer.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Extraperitoneal laparoscopic radical prostatectomy (E-LRP) and transperitoneal robotic-assisted laparoscopic radical prostatectomy (TRA-LRP) are two types of radical prostatectomy widely used at present, but the comparative study between them is limited. We aimed to compare E-LRP with TRA-LRP in the treatment of low- or intermediate-risk prostate cancer (PCa). Methods: From June 2020 to May 2024, in our department, a total of 80 patients with low- or intermediate-risk PCa, including 45 cases who received E-LRP (E-LRP group) and another 35 cases who received TRA-LRP (TRA-LRP group), were enrolled in our research. All patients were followed up for 6-24 months. Perioperative parameters, erectile function, urinary continence, and biochemical recurrence were compared between the 2 groups. Results: Patients in the TRA-LRP group had longer operative times (165.3 Conclusions: Compared with E-LRP, TRA-LRP can reduce the blood loss and PSM rate in low-risk or intermediate-risk PCa, and may help patients regain early continence and potency after operation. It may be superior in reducing intraoperative risk, improving oncological outcomes, and early postoperative rehabilitation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.